Ortho Regenerative Technologies Inc. (“Ortho” or the “Company”), a clinical-stage orthobiologics company focused on the development of novel soft tissue repair regenerative technologies, announced today that it has received, through its partnership with Polytechnique Montreal, a $500,000 non-dilutive grant from Axelys, to advance the development of its second technology platform indication, ORTHO-M, for meniscus repair.
Also Read: Phenomix Sciences Announces First Precision Obesity Biobanking Registry and Outcomes Study
“Obtaining this grant further demonstrates the strategic value of our close partnership with Polytechnique Montreal and consolidates the significant multi-indication potential of our drug/biologic PRP combination product for soft tissue repair”, said Philippe Deschamps, the Company’s CEO. “This research grant will be used to complete the preclinical development work for meniscus repair as a second high-value indication, in addition to the currently ongoing rotator cuff tears repair clinical program”, continued Deschamps.
There are approximately 600,000 meniscus repair operations in North America every year representing a $1 Billion market opportunity. Meniscus repair is yet again another soft tissue operation with a significant 20-40% failure rate that could potentially be helped by our drug/biologic/ PRP combination product.
Created in April 2021, Axelys is a non-profit organization whose mission is to contribute to the economic and social prosperity of Quebec by accelerating the development and transfer of high-potential innovations stemming from public research.
Axelys offers consulting and support services in development, intellectual property management and innovation transfer to all public research institutions in Quebec, in all regions. In addition, Axelys contributes to the creation of scientific companies spun off from public research.
Ortho is a clinical stage orthobiologics company dedicated to the development of novel therapeutic soft tissue repair technologies to dramatically improve the success rate of orthopedic and sports medicine surgeries. Our proprietary RESTORE technology platform is a proprietary muco-adhesive Chitosan-based biopolymer matrix, specifically designed to deliver biologics such as Platelet-Rich Plasma (PRP) or Bone Marrow Aspirate Concentrate (BMAC), to augment and guide the regeneration of new tissue in various musculoskeletal conditions. ORTHO-R, our lead Chitosan-PRP hybrid drug/biologic implant combination product, is formulated and designed to increase the healing rates of occupational and sports related injuries to tendons, meniscus and ligaments. Other formulations are being developed for cartilage repair, bone void filling and osteoarthritis treatment. The proprietary Chitosan-PRP combination ORTHO-R implant can be directly applied into the site of injury by a surgeon during a routine operative procedure without significantly extending the time of the surgery and without further intervention. Considering the significant potential of our technology platform, Ortho continues to assess new therapeutic target uses outside of the soft tissue repair field.